No products in the cart.
AAV9.LAMP2B gene therapy shows clinical benefit in Danon disease
1. In seven patients with Danon disease, a single infusion of adeno-associated virus serotype 9 carrying transgene LAMP2B (AVV9.LAMP2B) therapy...
Surgery Classics
Physician-written reports of landmark surgery studies
Coronary CT-angiography-guided management improves outcomes in patients with stable chest pain
1. Composite of coronary heart disease death and non-fatal myocardial infarction was less frequent in the CCTA group compared to...
Abelacimab reduces bleeding risk compared to rivaroxaban in atrial fibrillation
1. In this randomized controlled trial, abelacimab led to significantly lower rates of major or clinically relevant nonmajor bleeding compared...
Intraosseous and intravenous vascular access are equally effective for ROSC following out-of-hospital cardiac arrest
1. In this randomized clinical trial, among patients who had an out-of-hospital cardiac arrest, no significant difference was found in...
Intraosseous drug administration does not improve survival in out of hospital cardiac arrest
1. In this randomized trial, intraosseous-first vascular access did not result in higher 30-day survival than intravenous-first strategies in adults...
Transcatheter tricuspid-valve replacement provides mortality and quality of life benefits
1. In this randomized controlled trial, a transcatheter tricuspid-valve replacement provided a mortality benefit compared to standard medical therapy after...
Asundexian inferior to apixaban as anticoagulation therapy for atrial fibrillation
1. In this randomized controlled trial, among patients with atrial fibrillation requiring anticoagulation therapy, asundexian resulted in a high risk...
Vutrisiran reduces mortality in transthyretin amyloidosis with cardiomyopathy
1. Vutrisiran treatment reduced the risk of death and recurrent cardiovascular events compared to placebo in patients with transthyretin amyloidosis...
Spironolactone ineffective for patients with preserved ejection fraction after myocardial infarction
1. In this randomized controlled trial, spironolactone did not significantly reduce death from cardiovascular causes or new or worsening heart...
Colchicine not beneficial after acute myocardial infarction for reducing cardiovascular events
1. In this randomized controlled trial, in patients who had a myocardial infarction, a three-year treatment with colchicine was not...